A Randomized Trial of Recombinant Human C1-Esterase-Inhibitor in the Prevention of Contrast-Induced Kidney Injury
Anneza Panagiotou, Marten Trendelenburg, Ingmar A F M Heijnen, Stephan Moser, Leo H Bonati, Tobias Breidthardt, Gregor Fahrni, Christoph Kaiser, Raban Jeger, Michael Osthoff, Anneza Panagiotou, Marten Trendelenburg, Ingmar A F M Heijnen, Stephan Moser, Leo H Bonati, Tobias Breidthardt, Gregor Fahrni, Christoph Kaiser, Raban Jeger, Michael Osthoff
Abstract
Objectives: This study sought to determine the efficacy profile and safety of recombinant human C1 esterase inhibitor (rhC1INH) in the prevention of contrast-associated acute kidney injury after elective coronary angiography.
Background: Contrast-associated acute kidney injury is caused by tubular cytotoxicity and ischemia/reperfusion injury. rhC1INH is effective in reducing renal ischemia/reperfusion injury in experimental models.
Methods: In this placebo-controlled, double-blind, single-center trial 77 patients with chronic kidney disease were randomized to receive 50 IU/kg rhC1INH before and 4 h after elective coronary angiography or placebo. The primary outcome was the peak change of urinary neutrophil gelatinase-associated lipocalin within 48 h, a surrogate marker of kidney injury.
Results: Median peak change of urinary neutrophil gelatinase-associated lipocalin was lower in the rhC1INH group (4.7 ng/ml vs. 22.5 ng/ml; p = 0.038) in the per-protocol population but not in the modified intention-to-treat analysis, and in patients with percutaneous coronary interventions (median, 1.8 ng/ml vs. 26.2 ng/ml; p = 0.039 corresponding to a median proportion peak change of 11% vs. 205%; p = 0.002). The incidence of a cystatin C increase ≥10% within 24 h was lower in the rhC1INH group (16% vs. 33%; p = 0.045), whereas the frequency of contrast-associated acute kidney injury was comparable. Adverse events during a 3-month follow-up were similarly distributed.
Conclusions: Administration of rhC1INH before coronary angiography may attenuate renal injury as reflected by urinary neutrophil gelatinase-associated lipocalin and cystatin C. The safety profile of rhC1INH was favorable in a patient population with multiple comorbidities. (Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects [PROTECT]; NCT02869347).
Keywords: contrast-induced acute kidney injury; coronary angiography; cystatin C; neutrophil gelatinase-associated lipocalin; recombinant C1 esterase inhibitor.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed